Clearmind Medicine Appoints New Chief of Global Impact
Clearmind Medicine Inc. (Nasdaq: CMND), a prominent clinical-stage biotech company, has announced the strategic appointment of Mary-Elizabeth Gifford as its new Chief of Global Impact. In her role, Gifford will focus on strengthening partnerships in the U.S. while enhancing governmental engagement and regulatory advocacy initiatives. This move aims to connect groundbreaking research with regulatory frameworks, ultimately improving patient care with innovative psychedelic medicines.
Mary-Elizabeth Gifford's Background and Vision
Before joining Clearmind, Gifford played a pivotal role at Psyence BioMed, where she served as Chief of Global Impact. Her previous experience includes significant contributions at the Center for Mind-Body Medicine, a non-profit based in Washington, D.C. This diverse background equips her with the necessary skills to navigate complex regulatory environments and build valuable connections with stakeholders.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, expressed excitement over Gifford's appointment, emphasizing her deep knowledge of psychedelic policies and extensive experience collaborating with government officials and investors. He stated that her expertise will be crucial in positioning Clearmind as a frontrunner in the ethical development of patient-centered psychedelic therapeutics.
A Strong Commitment to Psychedelic Medicine
In her own words, Gifford conveyed her enthusiasm to join the innovative team at Clearmind Medicine. With a noteworthy portfolio of 31 granted patents, Clearmind is conducting clinical trials in esteemed institutions such as Yale School of Medicine and Johns Hopkins University. Gifford is dedicated to uphold the highest scientific standards and integrity in the psychedelic industry.
She also serves pro bono as the chair of the Psychedelics & Healing Initiative at the Global Wellness Institute, where she advocates for the responsible use of psychedelic therapies. Recognized for her influence in the industry, Gifford was named a "Psychedelic Titan" by Microdose, identifying her as one of the key figures in the psychedelic medicine field.
Recent Contributions and Industry Engagement
Mary-Elizabeth Gifford has actively participated in various forums addressing psychedelic ethics. Notably, she chaired the steering committee for the inaugural Federal Psychedelic Summit. Her contributions to discussions on psychedelic business ethics and "Profit with Purpose" at notable conferences further highlight her commitment to the field.
In July of 2025, she distinguished herself as the only biopharma executive selected to attend a rigorous program on psychedelic policy and law at Harvard Law School, solidifying her status as a leading voice in the psychedelic healthcare sector. A proud graduate of Brown University, Gifford also pursued post-graduate studies focused on the intersection of mind-body medicine and its historical context at Harvard.
About Clearmind Medicine Inc.
Clearmind Medicine Inc. specializes in the clinical development of psychedelic-derived therapeutics aimed at addressing myriad health challenges, including alcohol use disorder. Their mission is to innovate and commercialize psychedelic-based compounds as regulated medicines, food, or supplements, preserving a keen focus on research and the expansion of their intellectual property portfolio, which currently includes nineteen patent families and 31 granted patents.
As a publicly traded company, shares of Clearmind are listed on Nasdaq under the ticker symbol "CMND" and on the Frankfurt Stock Exchange as "CWY0.F," highlighting its commitment to investor transparency and growth in the evolving wellness sector.
Frequently Asked Questions
Who is Mary-Elizabeth Gifford?
Mary-Elizabeth Gifford is the newly appointed Chief of Global Impact at Clearmind Medicine. She has extensive experience in psychedelic policies and regulatory advocacy.
What role will Gifford play in Clearmind?
Gifford will enhance partnerships and governmental advocacy for Clearmind, helping to advance their psychedelic therapeutic initiatives.
What is Clearmind Medicine's focus?
Clearmind Medicine focuses on the discovery and development of psychedelic-derived therapeutics to address major health problems.
Where are Clearmind's clinical trials being conducted?
Clinical trials are currently underway at Yale School of Medicine, Johns Hopkins University, and Hadassah University Medical Center.
What are Clearmind's stock symbols?
Shares of Clearmind are traded on Nasdaq under "CMND" and at the Frankfurt Stock Exchange as "CWY0.F."
